Editor-in-Chief: Godefridus J. Peters
Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision: 63 days

Cancer Drug Resistance

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN

Articles

Most Recent | Most Viewed | Most Downloaded

Mitochondrial genome variability and metabolic alterations reveal new biomarkers of resistance in testicular germ cell tumors

Open Access Original Article DOI: 10.20517/cdr.2024.141 17 Dec 2024
Views: Downloads:
Download PDF

Ovarian tumor microenvironment contributes to tumor progression and chemoresistance

Open Access Review DOI: 10.20517/cdr.2024.111 16 Dec 2024
Views: Downloads:
Download PDF

Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer

Open Access Review DOI: 10.20517/cdr.2024.166 15 Dec 2024
Views: Downloads:
Download PDF

CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma - a short report

Open Access Original Article DOI: 10.20517/cdr.2024.149 12 Dec 2024
Views: Downloads:
Download PDF

Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment

Open Access Review DOI: 10.20517/cdr.2024.107 11 Dec 2024
Views: Downloads:
Download PDF

Venetoclax resistance: mechanistic insights and future strategies

Open Access Review DOI: 10.20517/cdr.2021.125 5 May 2022
Views: Downloads:
Download PDF

Improving HER2 testing reproducibility in HER2-low breast cancer

Open Access Opinion DOI: 10.20517/cdr.2022.29 31 Aug 2022
Views: Downloads:
Download PDF

Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces

Open Access Review DOI: 10.20517/cdr.2022.20 1 Aug 2022
Views: Downloads:
Download PDF
For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Articles Collection
The journal Cancer Drug Resistance has established a media partnership with the 5th EMBL Partnership Conference AI in one health.
The journal Cancer Drug Resistance has established a media partnership with the European Molecular Biology Laboratory (EMBL) for the upcoming EMBL Symposium - Mechanisms of drug resistance and tolerance in bacteria, fungi, and cancer.
On November 4, 2024, the editorial team sat down with Prof. David A. Gewirtz, a leading scientist in oncology research and an esteemed member of the journal’s Editorial Board.
On September 16, 2024, Stanford University and Elsevier jointly released the list of the world’s top 2% scientists.
We are pleased to announce that our journal, Cancer Drug Resistance (CDR), has obtained a new Impact Factor 2023 of 4.6, as reported by the Journal Citation Reports (JCR) released by Clarivate Analytics on June 20, 2024.

Interview with Professor David A. Gewirtz: Exploring Breakthroughs in Cancer Drug Resistance and Treatment [Embedded Auto-Generated Subtitles]

NaN
Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/